If you are asking what is new with the DEA and cannabis, the short answer is this: the Drug Enforcement Administration has proposed moving marijuana from Schedule I to Schedule III of the Controlled Substances Act, and that proposal is still not final. Until a final rule takes effect, cannabis remains a Schedule I substance under federal law, the strictest category the law uses, even in states that allow medical or adult-use sales.
DEA Position on Cannabis: Recent News and Schedule I Status
Everything else, from administrative hearings to hemp enforcement letters, follows from that unresolved question. Below is a plain-language guide to the moving parts, what they change, and what they do not.
cannabis descheduling dea update
Why the DEA decides this at all
The Controlled Substances Act puts scheduling authority in federal hands. DEA administers the law, sets production quotas, issues registrations, and enforces the rules. When a substance is petitioned for rescheduling, the Department of Health and Human Services reviews the science first and makes a recommendation. DEA then decides whether to act on it.
related article
That sequence is exactly what happened here. HHS completed its scientific review in 2023 and recommended that marijuana be placed in Schedule III. In May 2024, DEA published a proposed rule in the Federal Register to do that, then opened a public comment period.
Where the process stands now
The proposal went to an administrative law judge, who held a prehearing conference and then scheduled evidentiary hearings. Supporters, opponents, state officials, and industry groups were allowed to testify and cross-examine witnesses. Those proceedings have stretched across multiple sessions.
No deadline forces a decision. In the end, DEA can publish a final rule, revise the proposal, or withdraw it entirely. That uncertainty is the main thing to understand about what is new with the DEA and cannabis.
What Schedule III would change
- Accepted medical use: moving marijuana to Schedule III would formally recognize medical value under federal law.
- Tax treatment: Section 280E of the tax code currently limits deductions for businesses trafficking in Schedule I and II substances. Schedule III removes that pressure.
- Research access: researchers would face fewer registration and sourcing barriers.
- Criminal penalties: federal trafficking penalties would be lower, though they would not disappear.
What Schedule III would not change
- It would not legalize recreational cannabis.
- It would not make state-licensed retail sales lawful under federal law.
- It would not create a national commercial market or allow interstate shipping.
- It would not make cannabis a prescription drug sold at a pharmacy. That still requires FDA approval.
In other words, rescheduling is a regulatory shift, not legalization.
Hemp, delta-8, and DEA enforcement
The 2018 Farm Bill removed hemp, defined as cannabis with no more than 0.3 percent delta-9 THC on a dry weight basis, from the definition of marijuana. DEA has since sent letters to state regulators signaling that products containing controlled THC outside that definition can still be treated as controlled substances, and that THC produced through synthesis may fall outside the hemp exemption. State laws on intoxicating hemp products vary widely and continue to change.
Research quotas and licensed growers
DEA sets annual aggregate production quotas for controlled substances, including cannabis grown for research. The agency has also registered additional growers beyond the single long-standing supplier, which gives researchers more sources and variety. This matters to scientists and drug developers more than to retail customers.
What this means at the counter
State-legal does not mean federally legal. Federal appropriations riders have for years blocked the Justice Department from using funds to interfere with state medical cannabis programs, and those riders must be renewed. Practically speaking, that is why dispensaries operate openly in legal states while cannabis remains a controlled substance. Keep purchases within your state, follow possession limits, and avoid carrying product across state lines or through airports.
What to watch next
- A final DEA rule, a revised proposal, or a withdrawal.
- Court challenges from whichever side loses the administrative fight.
- Congressional action that could speed up or block the change.
- New federal or state rules on hemp-derived intoxicating cannabinoids.
- Renewal of the appropriations rider that shields state medical programs.
Key takeaways
- Cannabis is still Schedule I today.
- The DEA proposed Schedule III in May 2024 and has not finalized it.
- Rescheduling would ease taxes and research barriers, but it would not legalize sales.
- Hemp-derived THC enforcement remains unsettled.